ReviewFrontiers in microbiology2018
Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.
Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 177 citations in OpenAlex.
- Comparative Efficacy of Terbinafine, Itraconazole, and Griseofulvin in Treatment of Steroid-Modified Tinea.Indian dermatology online journal · 2026Article
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Multifunctional Activity ofPlants (Basel, Switzerland) · 2026Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Refractory Dermatophytosis in a Spitz Dog Successfully Managed with Posaconazole: A Case Report.Animals : an open access journal from MDPI · 2026Article
- Sensitivity of Dermatophytes to Terbinafine: World Experience and Recent Findings from Kazakhstan.Antibiotics (Basel, Switzerland) · 2026Article
- Global Emergence ofInfection and drug resistance · 2026Review
- Innovative green niosomal piperlongumine as a novel topical treatment for dermatophytosis in guinea pigs model.Scientific reports · 2025Article
- Dermatophyte-Selective Imidazole-Thiosemicarbazides: Potent In Vitro Activity AgainstInternational journal of molecular sciences · 2025Article
- Emerging Antifungal Resistance in Dermatophytosis: A Clinicomycological Study From North India.Cureus · 2025Article
- Fungal Pathogens in Pet Dogs and Cats in Grenada: Identification and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2025Article
- Onychomycosis in special populations.Future microbiology · 2025Review
- Dermatophytosis in context of Trichophyton rubrum: host defense mechanisms, virulence factors, and treatment innovations.Molecular biology reports · 2025Review
- Characterization of Biofilm Formation by the DermatophyteJournal of fungi (Basel, Switzerland) · 2025Article
- Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Unlocking the Skin-Protective Effects ofAntibiotics (Basel, Switzerland) · 2025Article
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- Chemical profile, antioxidant, antifungal, and cytotoxic activities of propolis from the stingless bee Tetragona clavipes.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Synthesis, Physicochemical Properties and Anti-Fungal Activities of NewInternational journal of molecular sciences · 2025Article
- Proteomic and metabolomic profiling reveals the fungicidal mechanisms ofFrontiers in microbiology · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatophytes comprise pathogenic fungi that have a high affinity for the keratinized structures present in nails, skin, and hair, causing superficial infections known as dermatophytosis. A reasonable number of antifungal drugs currently exist on the pharmaceutical market to control mycoses; however, their cellular targets are restricted, and fungi may exhibit tolerance or resistance to these agents. For example, the stress caused by antifungal and cytotoxic drugs in sub-inhibitory concentrations promotes compensatory stress responses, with the over-expression of genes involved in cellular detoxification, drug efflux, and signaling pathways being among the various mechanisms that may contribute to drug tolerance. In addition, the ATP-binding cassette transporters in dermatophytes that are responsible for cellular efflux can act synergistically, allowing one to compensate for the absence of the other, revealing the complexity of drug tolerance phenomena. Moreover, mutations in genes coding for target enzymes could lead to substitutions in amino acids involved in the binding of antifungal agents, hindering their performance and leading to treatment failure. The relevance of each one of these mechanisms of resistance to fungal survival is hard to define, mainly because they can act simultaneously in the cell. However, an understanding of the molecular mechanisms involved in the resistance/tolerance processes, the identification of new antifungal targets, as well as the prospective of new antifungal compounds among natural or synthetic products, are expected to bring advances and new insights that facilitate the improvement or development of novel strategies for antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.